The WATCHMAN FLX device showed superior safety with 8.5% major bleeding at 36 months, compared to 18.1% with oral ...
Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.
Three years after the U.S. FDA approval of Abbott Laboratories’ Amplatzer Amulet, results of its investigational device exemption trial failed to notably differentiate Abbott’s left atrial appendage ...
GlobalData on MSN1d
Boston Scientific reports outcomes from trial of LAAC deviceThe trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.
Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...
Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Larry ...
(RTTNews) - Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrirl Appendage Closure (LAAC) ...
The Cottage Heart & Vascular Center’s structural heart team at Santa Barbara Cottage Hospital (SBCH) recently performed their ...
Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback